Halozyme Therapeutics (HALO) Misses Q3 EPS by 2c
Tweet
Share
E-mailGet Alerts HALO Hot Sheet
Price: $107.12 +0.59%
EPS Growth %: +23.8%
Financial Fact:
Product sales: 13.33M
Today's EPS Names:
PMCB, PLCE, DOMO, More
EPS Growth %: +23.8%
Financial Fact:
Product sales: 13.33M
Today's EPS Names:
PMCB, PLCE, DOMO, More
Join SI Premium – FREE
Halozyme Therapeutics (NASDAQ: HALO) reported Q3 EPS of ($0.16), $0.02 worse than the analyst estimate of ($0.14). Revenue for the quarter came in at $14.6 million versus the consensus estimate of $16.5 million.
For earnings history and earnings-related data on Halozyme Therapeutics (HALO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Gap taps Coach architect Reed Krakoff for $29.95-$498 handbag line
- Why JPM thinks rising bond yields won’t derail the equity rally
- Hawaiian Electric trades at 8.8x P/E, but wildfire risk clouds value case
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
